EMoMiS: A Pipeline for Epitope-based Molecular Mimicry Search in Protein Structures with Applications to SARS-CoV-2

Motivation Epitope-based molecular mimicry occurs when an antibody cross-reacts with two different antigens due to structural and chemical similarities. Molecular mimicry between proteins from two viruses can lead to beneficial cross-protection when the antibodies produced by exposure to one also react with the other. On the other hand, mimicry between a protein from a pathogen and a human protein can lead to auto-immune disorders if the antibodies resulting from exposure to the virus end up interacting with host proteins. While cross-protection can suggest the possible reuse of vaccines developed for other pathogens, cross-reaction with host proteins may explain side effects. There are no computational tools available to date for a large-scale search of antibody cross-reactivity. Results We present a comprehensive Epitope-based Molecular Mimicry Search (EMoMiS) pipeline for computational molecular mimicry searches. EMoMiS, when applied to the SARS-CoV-2 Spike protein, identified eight examples of molecular mimicry with viral and human proteins. These findings provide possible explanations for (a) differential severity of COVID-19 caused by cross-protection due to prior vaccinations and/or exposure to other viruses, and (b) commonly seen COVID-19 side effects such as thrombocytopenia and thrombophilia. Our findings are supported by previously reported research but need validation with laboratory experiments. The developed pipeline is generic and can be applied to find mimicry for novel pathogens. It has applications in improving vaccine design. Availability The developed Epitope-based Molecular Mimicry Search Pipeline (EMoMiS) is available from https://biorg.cs.fiu.edu/emomis/. Contact giri@cs.fiu.edu

[1]  G. Narasimhan,et al.  Epitopedia: identifying molecular mimicry between pathogens and known immune epitopes , 2021, bioRxiv.

[2]  A. Zoufaly,et al.  Platelet Phenotype Analysis of COVID-19 Patients Reveals Progressive Changes in the Activation of Integrin αIIbβ3, F13A1, the SARS-CoV-2 Target EIF4A1 and Annexin A5 , 2021, Frontiers in Cardiovascular Medicine.

[3]  G. Narasimhan,et al.  Spike mimicry of thrombopoietin may induce thrombocytopenia in COVID-19 , 2021 .

[4]  M. Beltramello,et al.  Broad betacoronavirus neutralization by a stem helix–specific human antibody , 2021, Science.

[5]  Oriol Vinyals,et al.  Highly accurate protein structure prediction with AlphaFold , 2021, Nature.

[6]  D. Ho,et al.  Neutralizing antibody 5-7 defines a distinct site of vulnerability in SARS-CoV-2 spike N-terminal domain , 2021, bioRxiv.

[7]  D. Santander-Gordón,et al.  A novel in silico method for the molecular mimicry detection finds a formin with the potential to manipulate maize cell cytoskeleton. , 2021, Molecular plant-microbe interactions : MPMI.

[8]  B. Haynes,et al.  Effect of natural mutations of SARS-CoV-2 on spike structure, conformation, and antigenicity , 2021, Science.

[9]  T. Lotti,et al.  COVID‐19 and human papillomavirus: Paradoxical immunity , 2021, Journal of cosmetic dermatology.

[10]  D. Stuart,et al.  The antigenic anatomy of SARS-CoV-2 receptor binding domain , 2021, Cell.

[11]  D. Ho,et al.  Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite , 2021, bioRxiv.

[12]  S. Elledge,et al.  Structural basis for antibody inhibition of flavivirus NS1–triggered endothelial dysfunction , 2021, Science.

[13]  S. Subramaniam,et al.  Glycan reactive anti-HIV-1 antibodies bind the SARS-CoV-2 spike protein but do not block viral entry , 2021, Scientific Reports.

[14]  Limin Wang,et al.  Predictors of mortality in patients with coronavirus disease 2019: a systematic review and meta-analysis , 2020, BMC Infectious Diseases.

[15]  A. Walls,et al.  Structural basis for broad coronavirus neutralization , 2020, Nature Structural & Molecular Biology.

[16]  D. Stuart,et al.  ­­­The Antigenic Anatomy of SARS-CoV-2 Receptor Binding Domain , 2020, SSRN Electronic Journal.

[17]  J. V. Van Eyk,et al.  BCG vaccination history associates with decreased SARS-CoV-2 seroprevalence across a diverse cohort of healthcare workers. , 2020, The Journal of clinical investigation.

[18]  J. Lau,et al.  Thromboembolic complications of COVID-19 , 2020, Emergency Radiology.

[19]  P. Moceri,et al.  High Prevalence of Acquired Thrombophilia Without Prognosis Value in Patients With Coronavirus Disease 2019 , 2020, Journal of the American Heart Association.

[20]  S. Sethi,et al.  Cross-reactivity of SARS-CoV-2 with HIV chemiluminescent assay leading to false-positive results , 2020, Journal of Clinical Pathology.

[21]  R. Kolodny,et al.  Potential Antigenic Cross-reactivity Between Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Dengue Viruses , 2020, Clinical Infectious Diseases.

[22]  S. Subramaniam,et al.  Plasmin Cascade Mediates Thrombotic Events in SARS-CoV-2 Infection via Complement and Platelet-Activating Systems , 2020, IEEE Open Journal of Engineering in Medicine and Biology.

[23]  A. Venkatakrishnan,et al.  Exploratory analysis of immunization records highlights decreased SARS-CoV-2 rates in individuals with recent non-COVID-19 vaccinations , 2020, Scientific Reports.

[24]  K. Basu,et al.  Dengue antibodies can cross-react with SARS-CoV-2 and vice versa-Antibody detection kits can give false-positive results for both viruses in regions where both COVID-19 and Dengue co-exist , 2020, medRxiv.

[25]  Jordan Graves,et al.  A Review of Deep Learning Methods for Antibodies , 2020, Antibodies.

[26]  Tingjun Hou,et al.  Comprehensive Evaluation of Fourteen Docking Programs on Protein-Peptide Complexes and A New Strategy for Improving the Performance of Global Docking. , 2020, Journal of chemical theory and computation.

[27]  Matthijs Oudkerk,et al.  Diagnosis, Prevention, and Treatment of Thromboembolic Complications in COVID-19: Report of the National Institute for Public Health of the Netherlands , 2020, Radiology.

[28]  Yuan Yu,et al.  Thrombocytopenia and its association with mortality in patients with COVID‐19 , 2020, Journal of Thrombosis and Haemostasis.

[29]  S. Harrison,et al.  Cryo-EM structure of full-length HIV-1 Env bound with the Fab of antibody PG16. , 2020, Journal of molecular biology.

[30]  Genki Terashi,et al.  Protein docking model evaluation by 3D deep convolutional neural networks , 2019, Bioinform..

[31]  Daniel C. Stanzione,et al.  Lessons Learned from the Chameleon Testbed , 2020, USENIX Annual Technical Conference.

[32]  M. Bronstein,et al.  Deciphering interaction fingerprints from protein molecular surfaces using geometric deep learning , 2019, Nature Methods.

[33]  D. Egan,et al.  CD40/anti-CD40 antibody complexes which illustrate agonist and antagonist structural switches , 2019, BMC Molecular and Cell Biology.

[34]  Chris Bailey-Kellogg,et al.  Learning Context-aware Structural Representations to Predict Antigen and Antibody Binding Interfaces , 2019, bioRxiv.

[35]  Alessandro Sette,et al.  The Immune Epitope Database (IEDB): 2018 update , 2018, Nucleic Acids Res..

[36]  T. Bhardwaj,et al.  In silico identification of molecular mimics involved in the pathogenesis of Clostridium botulinum ATCC 3502 strain. , 2018, Microbial pathogenesis.

[37]  J. Kowal,et al.  Structure of a zosuquidar and UIC2-bound human-mouse chimeric ABCB1 , 2018, Proceedings of the National Academy of Sciences.

[38]  A. Makhov,et al.  High-Resolution Structure Analysis of Antibody V5 and U4 Conformational Epitopes on Human Papillomavirus 16 , 2017, Viruses.

[39]  Vanessa Sochat,et al.  Singularity: Scientific containers for mobility of compute , 2017, PloS one.

[40]  Jean-Christophe Nebel,et al.  Progress and challenges in predicting protein interfaces , 2015, Briefings Bioinform..

[41]  Edward T. Eng,et al.  β-Subunit Binding Is Sufficient for Ligands to Open the Integrin αIIbβ3 Headpiece* , 2015, The Journal of Biological Chemistry.

[42]  Gert Vriend,et al.  A series of PDB related databases for everyday needs , 2010, Nucleic Acids Res..

[43]  Jiye Shi,et al.  SAbDab: the structural antibody database , 2013, Nucleic Acids Res..

[44]  Andrew C Doxey,et al.  Prediction of molecular mimicry candidates in human pathogenic bacteria , 2013, Virulence.

[45]  M. Glennie,et al.  Agonistic CD40 Antibodies and Cancer Therapy , 2013, Clinical Cancer Research.

[46]  Søren B. Padkjær,et al.  Structural analysis of B-cell epitopes in antibody:protein complexes. , 2013, Molecular immunology.

[47]  M. Cusick,et al.  Molecular mimicry as a mechanism of autoimmune disease. , 2012, Clinical reviews in allergy & immunology.

[48]  D. Peabody,et al.  A Pan-HPV Vaccine Based on Bacteriophage PP7 VLPs Displaying Broadly Cross-Neutralizing Epitopes from the HPV Minor Capsid Protein, L2 , 2011, PloS one.

[49]  D. Nilsson,et al.  Genome-Wide Identification of Molecular Mimicry Candidates in Parasites , 2011, PloS one.

[50]  Christine J. Bryson,et al.  Immunogenicity of protein therapeutics: The key causes, consequences and challenges. , 2010, Self/nonself.

[51]  Bartek Wilczynski,et al.  Biopython: freely available Python tools for computational molecular biology and bioinformatics , 2009, Bioinform..

[52]  J. Qin,et al.  Platelet integrin αIIbβ3: activation mechanisms , 2007 .

[53]  L. Cavacini,et al.  The Neutralization Properties of a HIV-Specific Antibody Are Markedly Altered by Glycosylation Events Outside the Antigen-Binding Domain1 , 2007, The Journal of Immunology.

[54]  Olivier Lichtarge,et al.  Recurrent use of evolutionary importance for functional annotation of proteins based on local structural similarity , 2006, Protein science : a publication of the Protein Society.

[55]  J. Skolnick,et al.  TM-align: a protein structure alignment algorithm based on the TM-score , 2005, Nucleic acids research.

[56]  W. Quint,et al.  Molecular diagnosis of human papillomavirus (HPV) infections. , 2005, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[57]  Takashi Kato,et al.  Structure of the receptor-binding domain of human thrombopoietin determined by complexation with a neutralizing antibody fragment , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[58]  K. Yoon,et al.  Antibody-dependent enhancement of virus infection and disease. , 2003, Viral immunology.

[59]  C. Begley,et al.  Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. , 2002, Blood.

[60]  I. Longden,et al.  EMBOSS: the European Molecular Biology Open Software Suite. , 2000, Trends in genetics : TIG.

[61]  R. Colvin,et al.  Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand , 2000, Nature Medicine.

[62]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[63]  R. Inman,et al.  Molecular mimicry and autoimmunity. , 1999, The New England journal of medicine.

[64]  Thomas L. Madden,et al.  Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. , 1997, Nucleic acids research.

[65]  M. Sanner,et al.  Reduced surface: an efficient way to compute molecular surfaces. , 1996, Biopolymers.